COMPOUND PROFILE / PROTEINS & BIOLOGICS
Maridebart Cafraglutide / MariTide.
Research draftMaridebart cafraglutide, also called MariTide or AMG 133, is a peptide-antibody conjugate investigated for metabolic disease.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Maridebart cafraglutide, also called MariTide or AMG 133, is a peptide-antibody conjugate investigated for metabolic disease.
Mechanism
It combines GLP-1 receptor agonism with GIP receptor antagonism.
Human research
Registered and reported clinical development must be evaluated by exact formulation and trial; this mechanism differs from GIP agonists.
Preclinical & other research
Preclinical work explored receptor combination and prolonged exposure.
Safety & unknowns
Gastrointestinal tolerability and effects of long exposure need clinical assessment.
Regulatory status
Investigational in reviewed sources; do not infer approval or equivalence to tirzepatide.
Reported use & evidence
The supplied Maridebart Cafraglutide / MariTide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.